Results suggest >30% of pts with a poor or ultrarapid CYP2D6 phenotype may experience an adverse outcome when prescribed codeine, tramadol, oxycodone, or hydrocodone. Itching, rash, or throat swelling were present in 9 (24%) patients. PGx testing may he
CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications. - PubMed - NCBI https://t.co/ApDqYskz9C
Another safety and efficacy issue #codeine - CYP2D6 phenotypes associated with adverse outcomes related to opioids https://t.co/zqufKP2d9U
CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications https://t.co/fo2MwFjX89 https://t.co/2tfdMfzIMV